Thanks for pointing that out (the portion of the positive NOI attributable to a change in derivative liability). I'd previously noted but since forgotten that detail, as I last reviewed the annual report over a month ago. I didn't intend to suggest otherwise by omission - I'd just briefly checked the OTC Markets financials tab, where such details aren't listed, before posting.
Nothing I say is a buy/sell/hold recommendation or financial advice. My posts are opinion only. Always review SEC and OTC Markets filings yourself for balance sheet, income vs. expenses, and especially toxic debt.